AEterna Zentaris - 53 Year Dividend History | AEZS
Historical dividend payout and yield for AEterna Zentaris (AEZS) since 1971. The current TTM dividend payout for AEterna Zentaris (AEZS) as of April 22, 2024 is $0.00. The current dividend yield for AEterna Zentaris as of April 22, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.009B |
$0.005B |
|
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
